当前位置:首页 - 行情中心 - 海翔药业(002099) - 财务分析 - 利润表

海翔药业

(002099)

  

流通市值:90.56亿  总市值:90.65亿
流通股本:16.17亿   总股本:16.19亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入1,676,630,297.771,196,440,659.01634,047,833.62,704,144,046.05
营业收入1,676,630,297.771,196,440,659.01634,047,833.62,704,144,046.05
二、营业总成本1,659,118,871.861,133,067,681.29642,125,9352,476,304,932.39
营业成本1,351,962,825.72954,191,308.84507,044,957.051,983,869,849.05
税金及附加20,460,638.6213,586,333.666,064,897.1321,275,593.38
销售费用20,980,735.913,468,704.374,774,771.926,281,248.93
管理费用227,190,357.1144,811,554.8268,243,126.28402,442,913.79
研发费用93,277,992.9163,086,22131,037,256.82144,913,364.27
财务费用-54,753,678.39-56,076,441.424,960,925.82-102,478,037.03
其中:利息费用26,953,434.2717,819,827.165,937,301.7236,547,413.92
其中:利息收入57,881,313.0341,612,923.419,544,807.5333,469,567.78
加:公允价值变动收益-43,795,000-64,158,310.669,263,400-19,584,100
加:投资收益-61,416,890.47-12,261,345.1520,088,599.64-22,752,481.05
资产处置收益9,835,648.8510,532,678.288,302,601.55290,870.85
资产减值损失(新)----83,768,346.92
信用减值损失(新)20,128,419.0512,733,951.7511,158,870.58-17,525,419.33
其他收益13,378,361.227,677,844.043,564,513.2824,899,325.8
营业利润平衡项目0000
四、营业利润-44,358,035.4417,897,795.9844,299,883.65109,398,963.01
加:营业外收入33,403.5552,136.3115,7001,533,586.55
减:营业外支出1,403,682.4902,985.37245,032.9910,129,439.41
利润总额平衡项目0000
五、利润总额-45,728,314.2917,046,946.9244,070,550.66100,803,110.15
减:所得税费用-6,248,974.78-1,391,744.312,221,604.1614,725,029.09
六、净利润-39,479,339.5118,438,691.2341,848,946.586,078,081.06
持续经营净利润-39,479,339.5118,438,691.2341,848,946.586,078,081.06
归属于母公司股东的净利润-38,588,053.7119,171,880.2942,101,946.6188,013,729.03
少数股东损益-891,285.8-733,189.06-253,000.11-1,935,647.97
(一)基本每股收益-0.020.010.020.05
(二)稀释每股收益-0.020.010.020.05
八、其他综合收益---4,223,614.22
归属于母公司股东的其他综合收益---4,223,614.22
九、综合收益总额-39,479,339.5118,438,691.2341,848,946.590,301,695.28
归属于母公司股东的综合收益总额-38,588,053.7119,171,880.2942,101,946.6192,237,343.25
归属于少数股东的综合收益总额-891,285.8-733,189.06-253,000.11-1,935,647.97
公告日期2023-10-312023-08-302023-04-252023-04-25
审计意见(境内)标准无保留意见
TOP↑